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Abstract Mitochondria play a key role in overall cell physi-
ology and health by integrating cellular metabolism with cel-
lular defense and repair mechanisms in response to physiolog-
ical or environmental changes or stresses. In fact, dysregula-
tion of mitochondrial stress responses and its consequences in
the form of oxidative stress, has been linked to a wide variety
of diseases including inborn errors of metabolism. In this re-
viewwewill summarize how the functional state of mitochon-
dria — and especially the concentration of reactive oxygen
species (ROS), produced in connection with the respiratory
chain — regulates cellular stress responses by redox regula-
tion of nuclear gene networks involved in repair systems to
maintain cellular homeostasis and health. Based on our own
and other’s studies we re-introduce the ROS triangle model
and discuss how inborn errors of mitochondrial metabolism,
by production of pathological amounts of ROS, may cause
disturbed redox signalling and induce chronic cell stress with
non-resolving or compromised cell repair responses and in-
creased susceptibility to cell stress induced cell death. We
suggest that this model may have important implications for
those inborn errors of metabolism, where mitochondrial
dysfunction plays a major role, as it allows the explanation
of oxidative stress, metabolic reprogramming and altered sig-
nalling growth pathways that have been reported in many of
the diseases. It is our hope that the model may facilitate novel
ideas and directions that can be tested experimentally and used
in the design of future new approaches for pre-symptomatic
diagnosis and prognosis and perhaps more effective treat-
ments of inborn errors of metabolism.
Introduction
The traditional view of inborn errors of metabolism (IEM) is
genetic defects in metabolic enzymes or transporters, which
result in accumulation of toxic substrates and/or a compro-
mised ability to synthesize essential compounds such as aden-
osine triphosphate (ATP). However, although these features of
IEM certainly are important, the application of system biolog-
ical approaches have revealedmore generalized mitochondrial
dysfunctions, involving disturbed redox balance and oxidative
stress as well as altered growth signalling pathways. Such
mitochondrial driven processes may add to the pathophysiol-
ogy and have recently been studied and documented in vari-
ous IEMs: respiratory chain disorders (Wei et al 2009; Wu
et al 2010, 2014; Elstner and Turnbull 2012; Koopman et al
2012, 2013; Zhang et al 2013), organic acidurias (Wajner and
Goodman 2011; Kolker et al 2013), fatty acid oxidation dis-
orders (Gregersen et al 2008; Gregersen and Bross 2010;
Olsen et al 2013) and metabolic neuromuscular disorders
(Cornelius et al 2014a). For most of these diseases, there is
still no or very limited insight into the specific molecular trig-
gers of mitochondrial dysfunction and into the cellular mech-
anisms that invoke chronic mitochondrial dysfunction, oxida-
tive stress and altered signalling growth pathways. Here we
summarize current knowledge of oxidative stress and
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mitochondrial dysfunction in IEM. We discuss how accumu-
lation of pathological levels of reactive oxygen species (ROS)
and oxidative damage may disturb healthy redox signalling
between mitochondrial function and cellular repair responses,
and causes disturbed cell growth control and increased stress
susceptibility.
Before discussing oxidative stress in IEM, we will give a
brief overview of the mechanisms by which mitochondria
integrate cellular metabolism with cellular defense and repair
mechanisms to maintain cellular homeostasis and health in
response to physiological or environmental changes or
stresses.
Coordinated expression of the mitochondrial
and nuclear genomes is critical in maintaining
functional and healthy mitochondria and cell
homeostasis
Reactive oxygen species (ROS) are essential for the complex
relationship between the nuclear and mitochondrial genomes
that was initiated a billion of years ago, when an aerobic bac-
terium was engulfed by an anaerobic cell and developed a
symbiotic relationship. In this new Eukaryotic cell, anaerobic
glycolytic energy production, through the nuclear genome and
cytosolic machinery, was integrated with the oxidative mito-
chondrion containing its own plasmid DNA (mtDNA). Since
thenmost of the mitochondrial genome has been transferred to
the nucleus, and the mtDNA codes for only 13 subunits of the
respiratory chain in addition to tRNAs and rRNAs needed for
their translation. The nuclear DNA codes for the remaining
respiratory chain components and other enzymes needed for
oxidative metabolism like those involved in the tricarboxylic
acid (TCA) cycle, fatty acid oxidation and amino acid oxida-
tion. It also codes for proteins needed for mtDNA replication
and transcription, and for proteins assisting in the import and
maturation of mitochondrial proteins, and for modulating the
dynamic structure of mitochondria, where healthy mitochon-
dria form a fused threadlike structure and damaged part of
mitochondria are removed by fission through a selective au-
tophagy process called mitophagy (see below). Thus, the nu-
clear genome codes and controls most of proteins needed for
mitochondrial structure and function, including providing the
cell with energy and biosynthetic intermediates needed for cell
growth and repair (reviewed in (Sanchis-Gomar et al 2014;
Suliman and Piantadosi 2014)).
ROS production and regulation of its damaging effects
Although ROS are generated from many sources, including
the Nox family of NADPH oxidases, cytochrome P450 en-
zymes and xanthine oxidase, over 90% of intracellular ROS is
produced insidemitochondria. ROS, in the form of superoxide
radical anions (O2
.-) are produced by incomplete reduction of
oxygen or by leak of electrons from the respiratory chain,
mostly complex I and III. However, also other mitochondrial
enzymes like complex II, the electron transfer flavoprotein
(ETF) and its ubiquinone oxidoreductase (ETF:QO), α-
ketogluterate dehydrogenase and glycerol-3-phosphate dehy-
drogenase have been implicated in ROS production (Dröse
and Brandt 2012; Goncalves et al 2015). Whereas all these
mitochondrial enzymes release superoxide in the matrix, com-
plex III releases superoxide both in the matrix and the inter-
membrane space. Superoxide is highly reactive and in toxic
levels can oxidize and damage the structure and function of
other molecules in the cell or react with nitric oxide (·NO) that
leads to the formation of the highly deleterious peroxynitrite
species (ONOO−). To prevent these harmful reactions, super-
oxide is rapidly converted into hydrogen peroxide (H2O2) by
the superoxide dismutases (SOD). In the presence of transition
metals such as iron or cupper, hydrogen peroxide can be fur-
ther reduced to the highly reactive hydroxyl radical (.OH) by
the Fenton reaction, or be detoxified to water by
peroxiredoxins (Prxs), glutathione peroxidases (GPxs) or cat-
alase. All these ROS scavenger enzymes function to limit
ROS or reactive nitrogen species (RNS) induced oxidative
damage, but important for the content of this review, also to
buffer cellular ROS species (especially H2O2), and bring them
to a level at which they function as signalling molecules be-
tween mitochondrial function and redox activation of cell
stress protective pathways (Bolisetty and Jaimes 2013)
(Fig. 1).
H2O2 can diffuse through membranes to the cytosol and
oxidize thiol residues in stress regulatory proteins — such as
transcription factors, kinases and phosphatases — to control
their activity in a concentration dependent manner (Marinho
et al 2014). Likewise, at increased ROS levels, electrophiles
— produced by oxidation of unsaturated fatty acids resulting
in lipid peroxidation products — can transfer their oxidation
state to proteins and regulate their function through the oxida-
tion of cysteine residues on the recipient proteins (Higdon et al
2012; Kansanen et al 2012). In that way, ROS and electro-
philes are parts of a redox signalling system involved in the
regulation of mitochondrial quality control pathways and
overall cell repair (Fischer et al 2012; Kotiadis et al 2014;
Levonen et al 2014). The activated pathways control the ac-
tivity of the antioxidant system and metabolic reprogramming
to decrease ROS production and also control the activity of
DNA repair, protein quality control systems and autophagy/
mitophagy to hinder damaged DNA, proteins and mitochon-
dria to cause further ROS production and cell death. If the
ROS increases above a required level, where these redox-
sensitive stress response pathways can no longer cope with
the increased ROS, apoptotic cell death pathways will be ac-
tivated to hinder necrosis and organ failure as will be
discussed further below.
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Integrated gene networks link mitochondrial biogenesis
and function to cell defense and repair systems
The distinct actors of the repair systems— such as antioxidant
enzymes, DNA repair enzymes, chaperones and proteases—
require energy and other mitochondrial products like NAD+
for their functional activity. Therefore, the cell needs to adapt
or expand its mitochondrial population during episodes of cell
damage by the induction of mitochondrial biogenesis
(Piantadosi and Suliman 2012). Mitochondria exist as a tubu-
lar network in the cells, and they are not generated de novo.
Rather, healthy mitochondria in the network are stimulated to
proliferate, while defective mitochondria are selected and re-
moved by mitophagy (Youle and van der Bliek 2012; Archer
2013). The peroxisome proliferator-activated receptor γ
(PPARγ) coactivator 1α protein (PGC-1α) is a major up-
stream regulator of the gene network that controls mitochon-
drial biogenesis. PGC-1α is activated and regulated by a mul-
titude of mechanisms (Scarpulla et al 2012; Suliman and
Piantadosi 2014). For the present discussion, we will focus
on its potential activation during oxidative conditions (Fig. 2).
The serine/threonine AMP-activated protein kinase
(AMPK) inhibits ATP consuming pathways and activates
ATP generating pathways, like mitochondrial biogenesis, fatty
acid oxidation and glycolysis (Shirwany and Zou 2014).
AMPK is an upstream activator of PGC-1α. It has been shown
that AMPK upon oxidation of certain cysteines by H2O2
c h a n g e s i t s c o n f o rm a t i o n , a n d t h e n ma y b e
autophosphorylated and activated in an AMP-dependent or
AMP- independen t manne r (Wu and Wei 2012 ;
Hagenbuchner and Ausserlechner 2013). The phosphorylated
AMPK then phosphorylates downstream transcription factors
like PGC-1α and the Forkhead box O (FOXO3a). FOXO3
belongs to the O subclass of the forkhead family of transcrip-
tion factors, which are involved in protection from oxidative
stress. The phosphorylated proteins then translocate to the
nucleus and FOXO3a binds directly to the promoters of anti-
oxidant and autophagy genes (Kops et al 2002; Chiribau et al
2008; Li et al 2009; Wu et al 2014). PGC-1α co-activates
transcription factors like the nuclear respiratory factors
(NRFs), which are involved in mitochondrial biogenesis and
dynamics and estrogen-related receptor α (ERRα), which ac-
tivates fatty acid oxidation enzymes. PGC-1α also co-
activates peroxisome proliferator-activated receptors like
PPARα, PPARβ and PPARγ, which bind to promoters of
fatty acid oxidation and antioxidant genes (Polvani et al
2012; Scarpulla et al 2012; Kemper et al 2014) as illustrated
in Fig. 2. FOXO3a can also bind to the nicotinamide
phosphoribosyltransferase (Nampt) gene promoter and induce
its transcription. Nampt induction results in increased NAD+
levels, which in turn support the de-acetylation activity of
sirtuins. Sirtuins are essential parts within nuclear-
mitochondrial communication, where SIRT1 — located in
the nucleus — de-acetylates and activates PGC-1α and
Fig. 1 Reactive oxygen species (ROS) regulate cellular stress responses
by redox regulation of transcription factors, phosphatases/kinases and
chromatin structure that control nuclear gene networks to maintain cellu-
lar homeostasis and health as described in the text. Most intracellular
ROS is produced inside mitochondria by the electron transport chain
(ETC). The NADPH oxidases (NOX) and the xanthine oxidase (XO) also
contribute to cellular ROS production. Superoxide (·O2
−) is the main
initial free radical species, which can be converted to other ROS and
reactive nitrogen species as described in the text. Abbreviations are:
GPxs; gluthathion peroxidases, Prxs; peroxiredoxines, HO-1;
hemeoxygenase-1, and SOD; superoxide dismutase
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FOX03a, and also indirectly activates AMPK by de-
acetylation and activation of the AMPK-activating protein
kinase LKB1. The mitochondrial located SIRT3 in turn de-
acetylates and activates many of the mitochondrial biogenesis
and repair enzymes expressed by these transcription factors,
such as respiratory chain and fatty acid oxidation enzymes,
MnSOD and isocitrate dehydrogenase 1 (reviewed in
(Houtkooper et al 2012; Brenmoehl and Hoeflich 2013)).
Fig. 2 An integrated gene network links mitochondrial biogenesis to cell
repair functions. AMPK and Nrf2 are central players in activating this
gene network during oxidative stress, as both proteins are activated by
redox modification of critical cysteine residues as described in the text.
Nrf2 directly binds to promoters of a number of antioxidant (HO-1, GPxs,
Prxs, catalase, SOD), anti-inflammatory proteins (IL10, IL1Ra), as well
as autophagy (p62) and proteasomal (PSMB5) proteins, and also to pro-
teins (G6PD, IDH1, ME), needed for synthesis and regeneration of the
antioxidant NADPH as described in the text. Sirtuin-1 (SIRT1) activates
AMPK via de-acetylation of LKB1, which subsequently triggers AMPK
activation by phosphorylation. Activated AMPK phosphorylates down-
stream targets like PGC-1α, which upon de-acetylation binds to and co-
activates transcription factors involved in mitochondrial biogenesis and
dynamics such as the nuclear respiratory factors (NRF-1 and NRF-2).
NRF-1 in turn binds to and modulates expression of other factors such
as mitochondrial DNA polymerase (Polγ) and mitochondrial transcrip-
tion factor A (Tfam), which regulate mtDNA replication and transcrip-
tion, and also binds to and activates a number of genes required for
oxidative phosphorylation (OXPHOS) through expression of respiratory
chain components. PGC-1α can also activate the nuclear estrogen-related
receptors (ERRα), which binds to the promoters of fatty acid oxidation
enzymes (FAO) and to the promoter of the NAD+-dependent deacetylase,
sirtuin-3 (SIRT3), which is required for post-translational activation of a
number of metabolic and antioxidant enzymes located inside mitochon-
dria. PGC-1α can also directly activate the expression of antioxidant and
FAO enzymes by co-activating PPARs. PPARs comprise three members;
PPARα, PPARβ and PPARγ, each responsible for tissue specific activa-
tion of FAO and antioxidant proteins, albeit with some overlap. When
activated any of the PPARs can induce the expression of PGC-1α.
Moreover, AMPK can phosphorylate the FOXO3a upon oxidative stress
to promote its nuclear translocation and expression of antioxidants
(MnSOD, catalase, Prxs) and autophagy (Atg5, LC3II) proteins.
FOXO3a also binds to the promoter of the AMPK-activating protein
kinase LKB1, the SIRT1 promoter and to the Nampt gene promoter and
induces NAD+ synthesis and further AMPK activation. AMPK also up-
regulates glycolysis by increasing fructose-2,6-biphosphate concentra-
tions through phosphorylation of PFK2. Finally, AMPK can phosphory-
late tuberous sclerosis complex 2 (TSC2) and thereby inhibit mTOR,
which is a negative regulator of authophagy and an activator of HIF-
1α. Thus, to sustain energy requiring repair function during cellular
stress, AMPK activates mitochondrial biogenesis and inhibits energy-
demanding cellular functions, such as cell growth, and immune re-
sponses. The inhibitory effects of AMPK on immune responses are likely
to be indirect and governed by downstream mediators such as SIRT1
mediated de-acetylation and inactivation of NF-κB. NF-κB signalling is
also kept in an inactive state by Nrf2. Nuclear translocation of NF-κB
requires activation by an IKKβ kinase, which like Nrf2 is targeted for
proteasomal degradation by Keap1. When Nrf2 is released from Keap1
by moderate increases in oxidative stress, there is an increase in unbound
Keap1 available for IKKβ binding, thus inhibiting the expression of NF-
κB target genes. Abbreviations not explained in the text are: Atg5; au-
tophagy protein 5, G6PD; glucose-6-phosphate dehydrogenase, IDH1;
isocitrate dehydrogenase 1, LC3II; the phosphatidylethanolamine form
of microtubule-associated protein 1A/1B-light chain 3, ME; malic en-
zyme, PFK2; phosphofructokinase 2, and PSMB5; proteasome subunit
beta type 5. The symbol B¤^ indicates that the proteins are inactivated by
SIRT1 mediated de-acetylation. Activated proteins are in black and re-
pressed once in grey
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Another important transcription factor, which becomes ac-
tivated upon oxidative stress is Nrf2. Under normal condi-
tions, Nrf2 is kept in the cytoplasm by Kelch like-ECH-
associated protein 1 (Keap1) and Cullin 3 (Cul3), which lead
to ubiquitination and degradation of Nrf2 by the proteasome.
Oxidative stress or electrophilic stress modify certain cysteine
residues in Keap1, and thereby inhibit Keap1-Cul3 mediated
degradation of Nrf2, which then translocates to the nucleus
and activates a number of antioxidative and anti-inflammatory
genes. Nrf2 can also bind and activate NRF-1 expression and
perhaps PGC-1α and PPARγ upon electrophilic or oxidative
stress, thereby connecting antioxidant functions with mito-
chondrial biogenesis (Piantadosi and Suliman 2012; Polvani
et al 2012; Baldelli et al 2013).
The gene networks that connect the processes of protein
quality control and mitophagy to mitochondrial biogenesis are
less well characterized. However, Nrf2 activation has been
reported to regulate the removal of misfolded proteins as well
as damaged mitochondria by increasing the expression of pro-
teasome subunits (PSMs) of the 26S proteasome (Kwak et al
2003), and expression of the autophagy adaptor protein p62
(Jain et al 2010), which is needed for the selective removal of
damaged mitochondria by mitophagy (Vives-Bauza et al
2010). At the same time, p62 has been shown to interact with
the Keap1-binding site of Nrf2, resulting in activation of Nrf2
and its downstream targets (Komatsu et al 2010). Moreover,
the nuclear respiratory chain factor NRF-2 has been suggested
to bind to the proximal promoter of the mitochondrial protease
LON (Pinti et al 2011).
As illustrated in Fig. 2, the activity of AMPK and the ex-
pression of PGC-1α, FOXO3a, PPARs, Nrf2 and sirtuins
seems to be linked by a positive feedback loop that ensures
coordinated expression of antioxidant and other survival
genes, as long as oxidative stress persists. At the same time,
the genes exert an anti-inflammatory action, inhibiting the
pro-inflammatory transcription factor, nuclear factor Kappa-
light-chain-enhancer of activated B cells (NF-κB) (Salminen
et al 2011; Polvani et al 2012). The activity of NF-κB is also
inhibited by AMPK-mediated phosphorylation and activation
of TSC1/2, which keeps mammalian target of rapamycin
(mTOR) in an inactive state as discussed in more details
below.
Thus, to support energy demanding processes of cell repair,
a fine-tuned coordination of mitochondrial biogenesis to the
cell’s antioxidant, anti-inflammatory, protein quality control
and autophagy functions has been developed. This integrated
network also reflects that ROS is a natural byproduct of mito-
chondrial respiratory chain activity, and consequently that the
development of mechanisms to handle ROS from cellular ox-
ygen metabolism has been essential through the evolution of
the eukaryotic cell.
Mild and transient oxidative stress conditions or energy
demanding processes, such as exercise and caloric restriction,
can induce mitochondrial biogenesis with its integrated repair
gene networks, and thereby produce a larger and healthier
population of mitochondria (Lopez-Lluch et al 2006; Safdar
et al 2011; Milisav et al 2012; Piantadosi and Suliman 2012;
Aquilano et al 2013; Rodell et al 2013). Such cells are more
adapted to handle a subsequent event of energy crisis or dam-
aging ROS levels, as for example in connection with an infec-
tion or ischemia. This concept that low levels of a mitochon-
drial damaging agent improve systemic defense mechanisms
by inducing an adaptive response has been named mitochon-
drial hormesis or mitohormesis (Demirovic and Rattan 2013;
Ristow and Schmeisser 2014). Thus, in healthy cells mito-
chondrial biogenesis, in combination with a basal level of
mitophagy, is a beneficial and essential process that maintains
or improves healthy cell stress responses (Baldelli et al 2014).
However, when mitochondria accumulate oxidative damage
— for example under pathological conditions in cells with
inborn errors ofmetabolism— the fine-tuned redox regulation
of integrated mitochondrial biogenesis and repair systems
may be disturbed, and contribute to the accumulation of oxi-
dative stress and cell damage as illustrated in Fig. 3a and b and
further discussed below.
Oxidative stress causes maladaptive mitochondrial
repair responses and chronic cell stress in inborn
errors of metabolism
ROS and cellular signs of oxidative stress in IEM have been
documented in a number of studies of patient cells, model
cells and animals. A detailed review of these data is outside
the scope of this review, and the reader is referred to compre-
hensive review papers that discuss this topic (Gregersen et al
2008; Wei et al 2009; Gregersen and Bross 2010; Wu et al
2010, 2014;Wajner and Goodman 2011; Koopman et al 2012,
2013; Kolker et al 2013; Olsen et al 2013; Cornelius et al
2014a).
The exact mechanisms bywhich IEM produce ROS are not
known. Defects in mitochondrial DNA or nuclear DNA, that
directly affect respiratory chain function or its supercomplex
integrity, may cause ROS by electron leak or by incomplete
reduction of oxygen, as described for gene defects in complex
I (Patsi et al 2008; Sharma et al 2011), complex II (Guo and
Lemire 2003; Huang and Lemire 2009) and the electron trans-
fer flavoproteins (Cornelius et al 2012, 2013; Rodrigues and
Gomes 2012). Other gene defects, not directly affecting respi-
ratory chain enzymes, may cause accumulation of misfolded
variant proteins or toxic metabolites that can interact with and
disturb the structural organization and function of the respira-
tory chain enzymes or their supercomplexes, and in that way
initiate the production of ROS as discussed in (Gregersen and
Bross 2010; Wajner and Goodman 2011; Olsen et al 2013).
Because of its proximity to the site of ROS production, and its
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lack of protecting repair enzymes and histone molecules,
mtDNA is particularly vulnerable to oxidative damage, and
when affected can cause further respiratory chain dysfunction
(Wu et al 2010). It is likely, that mtDNA damage, together
with moveable lipid peroxidation products, can propagate and
amplify a vicious cycle of oxidative damage and ROS produc-
tion in the mitochondrial membrane network with increasing
damage to its protein components.
These mechanisms can cause functional decline in respira-
tory chain function, sometimes with a metabolic
reprogramming towards a more glycolytic energy production,
which seems to be a hallmark of many IEM and in particularly
respiratory chain disorders (Smeitink et al 2001; Schapira
2006; Wajner and Goodman 2011; Kolker et al 2013;
Koopman et al 2013). As a consequence of this metabolic
shift, which is known as the Warburg effect, pyruvate from
glycolysis is mostly converted to lactate instead of being shut-
tled into the mitochondrion for further conversion to acetyl-
CoA and oxidation through the tricarboxylic acid (TCA) cycle
and oxidative phosphorylation. Although it is well established
that respiratory chain dysfunction and energy crisis can induce
metabolic reprogramming, an increasing amount of data sup-
port that Warburg-like shifting is essential for cellular
adaptation to oxidative stress (Grant 2008; Wu and Wei
2012; Holley et al 2013).
Below we will discuss recent findings in IEM, supporting
the hypothesis, that the Warburg effect flow in the shade of
oxidative cell stress responses through integration with
nutrient-sensing signalling growth pathways. The working
model in Fig. 3a is a modified version of the ROS triangle
model that we presented in a recent review, based on mito-
chondrial proteomic and cell stress studies on primary skin
fibroblasts derived from patients with various inborn errors
of fatty acid oxidation (Olsen et al 2013). According to the
working model in Fig. 3a, the first line of adaptive stress
responses is fueled by an AMPK-induced metabolic
reprogramming in which mitochondrial biogenesis, in combi-
nation with increased glycolysis, support bioenergetic
supporting molecules for the repair systems. The second line
of stress responses is characterized by a marked decrease in
mitochondrial respiration—most likely induced by a pseudo-
hypoxic HIF-1α response — to inhibit further electron leak-
age and ROS production from a damaged respiratory chain,
which would otherwise induce apoptosis or necrosis. The con-
sequences of the second line of stress responses are compro-
mised cell repair responses that drive a more pro-
Fig. 3 The ROS triangle model links increasing ROS and damage to
chronic stress adaptation with non-resolving repair responses (green
graphic), or compromised repair responses that drive a more pro-
inflammatory environment (orange graphic). The antagonistic cell stress
responses are linked to distinct cellular metabolism through redox-
sensitive nutrient-sensing signalling growth pathways that control a
Warburg-like shift from mitochondrial respiration (AMPK/PGC-1α) to-
wards mostly cytosolic glycolysis (mTOR/HIF-1α). ROS, but also
NAD+, are the most important mitochondrial signalling molecules that
drive the transition from one stage of the triangle to another as discussed
in the text and illustrated in Fig. 4. When oxidative stress becomes too
high to allow cell stress adaptive redox signalling, apoptosis and cell
death are induced (red graphic) (a). In the sick cell, chronic non-
resolving repair responses or inflammatory responses will dominate de-
pending on the duration and/or level of ROS load. In the healthy cell,
well-controlled physiological levels of ROS allow healthy redox signal-
ling and dynamic cell stress responses to ensure that inflammatory and
damaging cell responses are followed by repair responses to restore ho-
meostasis. The ROS range, at which dynamic healthy redox signalling is
taking place, to regulate transient physiological changes or stressors like
cell growth/differentiation and inflammation/repair, is called the
homeodynamic space. Mild and transient oxidative stress, such as exer-
cise and caloric restriction, increases the homeodynamic space by
boosting repair responses, and prevent chronic disease development.
IEM and other persistent ROS-inducers decrease the homeodynamic
space, making the cells more prone to chronic disease development (b)
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inflammatory environment. ROS is the most important trig-
gering factor, and it also drives the transition from one stage of
the triangle to another. We will argue for the model using
examples primarily from our own and other’s studies of mul-
tiple acyl-CoA dehydrogenation deficiency (MADD) caused
by mutations in the electron transfer flavoprotein:ubiquinone
oxidoreductase (ETF:QO). We will also include elegant and
illustrative studies carried out by Yau-Huei Wei’s lab on fibro-
blasts derived from patients with myoclonic epilepsy with
ragged-red fibres (MERRF) due to the common mtDNA
8344A>G tRNALys mutation.
Coordination of metabolic and repair functions to cope
with energy requirement and oxidative stress; the first line
of adaptive stress responses
Multiple acyl-CoA dehydrogenation deficiency (MADD) is a
disorder of mitochondrial metabolism in which mutant geno-
types have been linked to different ROS levels and clinical
phenotypes with secondary respiratory chain deficiency.
Primary skin fibroblasts from MADD patients may therefore
serve as good models to study how different levels of endog-
enous ROS regulate mitochondrial cell stress pathways and
cause respiratory chain dysfunction and disease.
MADD is caused by gene variations in electron transfer
flavoprotein (ETF) or its ubiquinone oxidoreductase (ETF-
QO). These two enzymes link a number of fatty acid and
amino acid dehydrogenation reactions to ATP production in
the respiratory chain, by delivering electrons to coenzyme
Q10 (CoQ10) and complex III (Watmough and Frerman
2010). A relationship between genotype and phenotype has
been documented in which patients with multi-organ failure
and neonatal or early childhood death carry gene defects that
cause severely decreased amount of protein and almost total
lack of enzyme activity. These patients are named Bsevere
MADD^ or S:MADD. Patients with later-onset of disease
and predominantly muscle symptoms carry gene defects that
give rise to milder folding defective proteins with enzyme
activities that can be modulated, and sometimes rescued by
FAD co-factor treatment in the form of riboflavin (Goodman
et al 2002; Olsen et al 2003, 2007; Cornelius et al 2012).
These patients are named Briboflavin-responsive MADD^ or
RR:MADD. Muscle biopsies from later-onset patients often
show secondary respiratory chain and CoQ10 deficiencies
combined with lipid storage (Gempel et al 2007; Olsen et al
2007; Wen et al 2010; Grunert 2014).
The ETF/ETF-QO complex — with its integrated flavin
and iron-sulfur clusters — has the capacity to produce ROS
during fatty acid oxidation (Goncalves et al 2015; St-Pierre
et al 2002), and at increased levels when fatty acid oxidation is
disturbed by mutations in ETF/ETF-QO (Rodrigues and
Gomes 2012; Cornelius et al 2013). By over-expression stud-
ies in HEK-293 cells, we recently showed that mild folding
defective variant ETF-QO proteins produce more ROS than
severe folding defective and degraded ETF-QO proteins
(Cornelius et al 2013). In accordance with these findings, a
proteomic study of fibroblasts from a S:MADD patient and
total lack of ETF-QO protein revealed signs of mild oxidative
stress by activation of cell repair pathways with increased
expression of antioxidant enzymes like MnSOD,
peroxiredoxin and glutathione reductase, and increased levels
of a number of heat shock proteins (Hsp90, Hsp70, Hsp78 and
Hsp60), which are part of the cellular protein quality control
system. This up-regulation of cellular repair systems was ac-
companied by increases in glycolytic enzymes and in cytosol-
ic isocitrate dehydrogenase 1, whereas fatty acid oxidation
enzymes were down-regulated and respiratory chain enzymes
showed a more mixed regulation (Rocha et al 2011). These
studies confirm well earlier studies in a S:MADD Zebrafish
model, which lacks ETF-QO protein due to an endogenous
defect. In this Zebrafish model, increased superoxide produc-
tion is associated with transcriptional up-regulating of glyco-
lytic enzymes along with the antioxidant enzymes glutathione
reductase and uncoupling protein 3, and the heat shock pro-
teins Hsp90 (Song et al 2009).
As mentioned, this up-regulation of glycolysis (Warburg-
like effect) is a general finding in IEM and is essential for their
adaptation, not only to energy crisis, but also to oxidative
stress. Oxidative stressed cells take up more glucose to fuel
them into the pentose phosphate pathway for production of
NADPH by glucose-6-phosphate dehydrogenase. Activation
of NADPH producing pathways, which besides glucose-6-
phosphate dehydrogenase also include cytosolic isocitrate de-
hydrogenase 1 and malic enzyme, is a hallmark of the
Warburg phenotype (Vander Heiden et al 2009). NADPH is
an essential co-factor for glutathione and thioredoxin
recycling, and thereby for H2O2 detoxification by glutathione
peroxidase and peroxiredoxin, which are regulated by the
Nrf2 system. Actually, many enzymes needed for synthesis
and regeneration of NADPH are Nrf2 targets themselves,
again illustrating a cellular need for coordination of antioxi-
dant defense mechanisms with metabolism (Heiss et al 2013)
(Fig. 2). Accordingly, Yau-HueiWei’s lab has shown that cells
from MERRF patients, with the common mtDNA 8344A>G
tRNALys mutation, show increased ROS, and decreased
NADPH and cell survival when glycolysis is inhibited by
genetic knockdown of AMPK or glucose depletion, indicating
that up-regulation of glycolysis is an oxidative stress protec-
tive mechanism (Wu and Wei 2012). Similarly, fibroblasts,
derived from patients with genetic defects of fatty acid oxida-
tion enzymes, and challenged with the ROS-inducing drug
menadione, die faster when depleted of glucose (Zolkipli
et al 2011). Importantly, Yau-Huei Wei’s lab showed that
AMPK can be activated in a H2O2-dependent and AMP-
independent manner (Wu and Wei 2012), and that activated
and phosphorylated AMPK levels in MERRF fibroblast cells
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correlate with increased phosphorylation and expression of a
number of downstream AMPK targets, such as PGC-1α, and
FOXO3a, which are transcription factors that control mito-
chondrial biogenesis, glycolysis and cell repair pathways, re-
spectively as described above (Wu and Wei 2012; Wu et al
2014). Accordingly, in addition to activation of glycolytic and
antioxidant enzymes, MERRF cells do also show accumula-
tion of autophagosomes and increased mitophagy, which can
be restored by ROS scavenger treatment in the form of CoQ10
(De la Mata et al 2012). The level of the phosphorylated and
active forms of AMPK is also significantly increased in the
MADD zebrafish (Song et al 2009). Together with the ob-
served increases in glycolytic and antioxidant genes, this in-
dicates that MADD cells may activate a similar nuclear gene
network as observed in MERRF cells.
All together these studies suggest that a first line of adap-
tive stress responses to mild oxidative stress could be ROS-
mediated activation of AMPK, which links metabolic
reprogramming and mitochondrial biogenesis with activa-
tion of stress repair pathways to protect the cell from oxida-
tive damage. Because of the inborn gene defects, the repair
responses may be non-resolving and persistent resulting in
over-proliferating mitochondria and the so-called ragged-red
fibers phenotype, which is a pathological hall mark of many
mtDNA diseases, including MERRF (Wu et al 2014).
Chronic over-proliferating mitochondria have been linked
to cardiomyopathies, which are common in IEM
(Sebastiani et al 2007; Bates et al 2012). Another conse-
quence of non-resolving mitochondrial biogenesis, during
oxidative stress, could be increased risk of molecular dam-
age spreading into the mitochondrial network, because of
the ongoing mitochondrial content mixing during repeated
and prolonged fission-fusion events. This may be one ex-
planation for the clonal expansion of mutant mitochondrial
DNA in respiratory chain disorders (Figge et al 2013) and
other diseases/conditions associated with mitochondrial dys-
function such as heart failure and aging (Wei et al 2009; Dai
et al 2010; Ahuja et al 2013). As time progresses, this could
also contribute to increasing oxidative stress and increasing
risk of irreversible structural damage that prevent redox ac-
tivation of cell repair pathways as discussed below, and
force the cell into the second line of adaptive stress
responses.
Decreased mitochondrial respiration and repair functions
to cope with redox stress and prevent cell death;
the second line of adaptive stress responses
With age and senescence, and under chronic disease condi-
tions, cells have compromised repair mechanisms, or seem to
lose their ability to induce them during acute stress. For ex-
ample MnSOD has been found decreased in a number of
studies of patient cells, model cells and animals with chronic
diseases, like diabetes, cardiovascular diseases, cancer and
kidney disease (Scott et al 2010; Bauer et al 2011; Charniot
et al 2011; Mohelnikova-Duchonova et al 2011; Olsson et al
2011). Similarly the Lon protease (Ngo et al 2013) and au-
tophagy and mitophagy processes (Salminen and Kaarniranta
2009; Bolisetty and Jaimes 2013), which are essential for
elimination of damaged mitochondrial proteins or organelles,
are decreased in the same or other diseases with chronic cell
stress, and so are anti-inflammatory proteins (Liu et al 2012;
Tabas and Glass 2013). Interestingly, mitochondrial biogene-
sis (Sanchis-Gomar et al 2014) and sirtuins (Yechoor et al
2004; Palacios et al 2009; Sundaresan et al 2009) are also
decreased, which as mentioned above, plays important roles
in coordinating the transcriptional and post-translational reg-
ulation of mitochondrial metabolism and antioxidant function
in response to energy and oxidative stress.
The mechanisms that drive these blunted repair responses
are still unknown and a subject of intensive research. Some
lessons can be learned from RR-MADD and other IEM.
Most of the patients suffering from RR-MADD have sec-
ondary respiratory chain and CoQ10 deficiency (Gempel
et al 2007; Olsen et al 2007; Wen et al 2010; Cornelius
et al 2013; Grunert 2014). Many of the gene defects are
located near the site of ubiquinone reduction, and our data
suggest that the ETF-QO ubiquinone-binding site can be-
come a source of relative intensive superoxide production
when the ETF-QO protein misfolds due to gene defects
(Cornelius et al 2012, 2013).
In contrast to what has been observed in S:MADD cells,
RR:MADD cells seem to have decreased levels of key pro-
teins involved in mitochondrial repair mechanisms. In a study,
in which fibroblast cells, derived from six unrelated RR-
MADD patients, were cultured and compared to that of con-
trol fibroblasts, RR-MADD cells showed decreases in the
protein levels of the antioxidant enzyme MnSOD, the protein
quality control enzyme Lon, and the p62 protein — which is
needed for recognition and selection of oxidative damage mi-
tochondria for autophagy degradation. Also mitofusin 2,
which is one of the key regulators of mitochondrial fusion
events during mitochondrial biogenesis and dynamics, was
decreased. Accordingly, the mitochondrial network had a
fragmented morphology (Cornelius et al 2014b). In addition
to decreased fatty acid oxidation enzymes, these RR:MADD
cells also showed decreased levels of SIRT3.
SIRT3 controls the activity of mitochondrial oxidative
phosphorylation and antioxidant function by direct de-
acetylation of key metabolic and antioxidant enzymes as de-
scribed above, and also indirectly by decreasing ROS-induced
stability of hypoxia-inducible factor-1α (HIF-1α). HIF-1α
regulates the expression of a gene network leading to the
Warburg effect and down-regulation of respiratory chain func-
tion in cancer cells (Bell et al 2011; Finley et al 2011;
Schumacker 2011; Huang et al 2014).
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Interestingly, treating the RR-MADD cells with CoQ10
decreased the amount of ROS production (Cornelius et al
2013), and to some extent reverted the decreased levels of
Lon, p62 and mitofusion 2, but did not significantly affect
the levels of Sirt3 and MnSOD (Cornelius et al 2014b). As
described above and illustrated in Fig. 2, MnSOD and SIRT3
— along with expression of fatty acid oxidation enzymes —
are regulated by the master regulator of mitochondrial biogen-
esis PGC-1α through its binding to and co-activation of the
PPARs and ERRα transcription factors, respectively. MnSOD
is also controlled by the FOXO3a transcription factor —
which, like PGC-1α, becomes phosphorylated and activated
upon ROS-induced activation of AMPK inMERRF cells (Wu
et al 2014). The transcriptional regulation of Lon and p62 is
not well known. However, it is likely that their expression is
also associated with mitochondrial biogenesis and oxidative
stress as discussed above and illustrated in Fig. 2.
Thus, it is likely that in RR:MADD cells, impaired activa-
tion of AMPK/PGC-1α/FOXO3a (the first line of adaptive
stress response) results in blunted repair responses, as shown
in cells from patients with Friedreich’s ataxia. These patients
suffer from mitochondrial dysfunction and oxidative stress
due to mutant frataxin, which is involved in the regulation
and maturation of iron-sulfur protein activities (Cornelius
et al 2014a) and references herein). It has been shown in
patient skin fibroblasts and in a frataxin knock-out mouse that
the decreased amount of PGC-1α results in decreased
MnSOD and a loss of MnSOD activation in response to oxi-
dative stress. This response can be restored by AMPK and
PPARγ agonists (Marmolino et al 2010).
Thus, severe or persistent oxidative stress load may induce
a state of chronic oxidative stress with compromised oxidative
stress protective responses that obviously will make the cells
more susceptible for further stress-induced disease and cell
death. This innate predisposition to stress induced cell death
is illustrated in a study in which cultured fibroblasts from
patients with genetic deficiencies of various fatty acid oxida-
tion enzymes, as compared to control cells, suffered from
early death when challenged with the ROS-inducing antican-
cer drug menadione (Zolkipli et al 2011). Interestingly, in the
same study survival was increased when the cells were treated
with antioxidants or the PPAR agonist bezafibrate, which
boosts PGC-1α mediated mitochondrial respiration and anti-
oxidant function. This suggests that also in these cells mito-
chondrial biogenesis and stress tolerance might be limited by
ROS induced AMPK/PGC-1α/FOXO3a/signalling defects.
Like bezafibrate, resveratrol is known to increase mitochon-
drial biogenesis and antioxidant function; although in a more
indirect manner by binding to and stimulating complex I,
thereby increasing the NAD+ and sirtuin-mediated activation
of mitochondrial respiration and antioxidant function
(Desquiret-Dumas et al 2013). Accordingly, not only
bezafibrate (Djouadi et al 2005; Gobin-Limballe et al 2007;
Bonnefont et al 2009, 2010; Li et al 2010; Casarin et al 2012;
Yamaguchi et al 2012), but also resveratrol (Lopes et al 2014;
Aires et al 2014; De Paepe et al 2014,), and the AMP analogue
and AMPK activator 5-aminoimidazole-4-carboxamide ribo-
nucleoside (AICAR) (Golubitzky et al 2011) have been shown
to boost fatty acid oxidation and respiratory chain capacity in
cells from patients with inborn errors of metabolism.
Although oxidative stress and mitochondrial stress responses
were not investigated, these data suggest that mitochondrial
biogenesis — and thereby activation of cellular repair re-
sponses through the AMPK/PGC-1α/FOXO3a/Nrf2 axis —
is disturbed by chronic oxidative stress, and respiratory chain
dysfunction, and that increased mitochondrial biogenesis can
be beneficial for these IEM.
AMPK constitutes together with mTOR the major signal-
ling nodes guiding intrinsic and extrinsic stress responses,
respectively. While AMPK favours glycolysis, coupled to mi-
tochondrial respiration, to generate energy for stress repair
mechanisms, mTOR switches on ATP-consuming anabolic
pathways like the synthesis of proteins, lipids and cholesterol
by activating among others HIF-1α to drive cellular growth
and proliferation in response to extern growth stimuli, like
nutrients and infecting pathogens (Laplante and Sabatini
2012). So, these two signalling pathways respond to stress
signals by antagonistic transcriptional and metabolic path-
ways and activation of one system prevents the activity of
the other. Key to this reciprocal regulation is AMPK-
mediated phosphorylation and activation of Raptor and the
tuberous sclerosis complex 2 (TSC2), which keep mTOR in
an inactive state. Likewise, whereas sirtuin-mediated de-acet-
ylation is needed for the activation of AMPK (through de-
acetylation of LKB1) and its down-stream targets, SIRT1-
mediated de-acetylation inactivates HIF-1α activity (Lim
et al 2010) and NF-κB (Kauppinen a salminen a al 2013)
(Fig. 2). Accordingly, primary cell cultures with impaired
AMPK signalling due to diverse IEM up-regulate the
mTOR/HIF-1α pathway (Zhang et al 2013).
It will be interesting to investigate if pro-inflammatory re-
sponses are activated in IEM tissue with compromised repair
responses in as much as decreased activations of these (ex.
Nrf2- and AMPK-connected pathways) theoretically should
force a more pro-inflammatory and pro-oxidant environment.
Such an environment can in itself activate and be sustained by
NF-κB-linked pro-inflammatory responses, which are
transactivated by increased HIF-1α activity and decreased
AMPK (Salminen et al 2011; Liu et al 2012; Piantadosi and
Suliman 2012). Dysfunctional mitochondria may also release
damage-associated molecular patterns (DAMPs), which can
stimulate inflammasomes and a systemic inflammatory re-
sponse in which NF-κB activation plays a priming role
(Zhang et al 2010; Zhou et al 2011). In fact it has recently
been shown, in Friedreich’s ataxia patient cells and in a
frataxin knock-out mouse, that such cells have increased
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levels of various pro-inflammatory prostaglandins and are
more sensitive to inflammatory stimulus (Hayashi et al
2014). Pro-inflammatory responses have been associated with
a number of other chronic diseases such as diabetes, obesity,
atherosclerosis and neurodegenerative diseases (Tabas and
Glass 2013). The stress responses of acute inflammation —
induced by infection/sepsis or tissue injury — are similar to
those of chronic inflammation with activation of the
mTOR/HIF-1α/NF-κB axis. However, the non-resolving
and simmering nature of chronic inflammation differs from
the intense acute responses, which switch to repair responses
within days/weeks to restore homeostasis. The mechanisms
responsible for this are unknown. It has been suggested that
proximal sensing and signalling mechanisms for inducing
chronic versus acute inflammation may differ (Liu et al
2012). Mitochondrial ROS could be the triggering factor of
chronic stress and inflammation as discussed below, and as
such, treatment of chronic inflammation should be directed
towards preventing accumulation of ROS and its associated
damage.
Triggers of chronic cell stress and transition from one
stage to the next
Lack of, or decreased amount of mitochondrial signalling
molecules, especially NAD+ — which through sirtuin medi-
ated de-acetylation activates the AMPK/PGC-1α/FOXO3a
signalling pathways — has been put forward to explain the
compromised mitochondrial function and repair mechanisms
in chronic disease conditions (Liu et al 2012; Nunnari and
Suomalainen 2012). In fact, recent transcriptomic studies of
cultured skin fibroblasts from a large group of respiratory
chain disorders, with various primary gene defects, revealed
altered AMPK/FOXO3a/PPAR signalling, which could be re-
versed by treating the fibroblasts with nicotinic acid (a precur-
sor for NAD+) to enhance sirtuin activity and improve cellular
respiratory chain activity (Zhang et al 2013).
Although dysfunctional NAD+ signalling certainly may act
to maintain and worsen the maladaptive stress responses, it
does not explain how these signalling molecules become ab-
normal in the first place. Of course, for mitochondrial diseases
with mutations in respiratory chain complexes, the decreased
NAD+ could be a direct effect of a compromised respiratory
chain activity, but for other IEM or diseases with more com-
plex genetics, which do not directly affect respiratory chain
function, other explanations may need to be put forward to
explain their blunted repair responses. As discussed here, tox-
ic misfolded proteins or accumulated substrates in IEM— but
also glycation end products in diabetes (Picard et al 2014) and
the formation of β-amyloids and tau aggregates in Alzheimer
disease (Bobba et al 2013; Pizzimenti et al 2013) — may
accumulate and interact with the respiratory chain and induce
oxidative stress, and/or act as DAMPs to stimulate ROS
production through inflammatory processes, as discussed
above. If ROS persist, or is not properly controlled by the
AMPK/Nrf2-linked repair pathways, the repair mechanisms
may be overloaded with the increasing risk of irreversible
damage to the respiratory chain and decline in mitochondrial
respiration and signalling.
In fact, it has been suggested that during chronic oxidative
stress, there is a bias towards redox deregulation by the intro-
duction of irreversible structural damage, which may also hit
repair enzymes. For example, it has been shown that intermo-
lecular disulfide bond formation between heat shock factor 1
(HSF1) proteins causes trimerization and DNA binding to the
proximal promoters of heat shock proteins, whereas an intra-
molecular disulfide bond formation inhibits the activity of the
transcription factor (Calabrese et al 2012). Similarly the Lon
protease can be inactivated by oxidants such as ONOO−
(Stanyer et al 2008). Therefore, we suggest that especially
the level and duration of cellular ROS load drives the decline
in cell repair mechanisms as exemplified by the studies on
RR:MADD cells, discussed above.
It is increasingly established that the level of ROS itself
may determine the type of the cell stress responses by modu-
lating the activity of different redox-sensitive transcription
factors, phosphatases and kinases. For instance, low ROS
levels induce Nrf2 for the induction of several antioxidant
and anti-inflammatory proteins as described above.
Moderate increases in ROS can activate HIF-1α by oxidation
of certain cysteine residues in HIF-1α regulatory proteins,
whereas further oxidation of other residues at higher ROS
levels inactivates HIF-1α and induces apoptosis (Page et al
2008; Wang et al 2012). In line with this, certain mutations in
the ubiquinone-binding sites of complex I and complex II
have been demonstrated to induce a pseudo-hypoxic metabol-
ic switch from mitochondrial respiration towards glycolytic
ATP production through activation of the Akt/HIF-1α path-
way and down-regulation of activated AMPK in a ROS dose
dependent manner (Guzy et al 2008; Sharma et al 2011).
Thus, during chronic cell stress, lack of mitochondrial
NAD+ to sustain activation of the AMPK/PGC-1α/FOXO3a
axis, and/or activation of the mTOR/HIF-1α axis at increasing
ROS levels may shift the cell from mitochondrial respiration
and active repair responses towards a more glycolytic metab-
olism with compromised repair mechanisms. In both scenari-
os, ROS is mainly produced and propagated by a damaged
respiratory chain (Fig. 4).
So what are the cellular or whole tissue/body advantages— if
any — of this second line of adaptive stress responses, which
seem to be widely conserved between different disease condi-
tions? We have speculated that during persistent or increasing
ROS load — during which the repair mechanisms may be
overloaded and irreversible structural damage increasingly is in-
troduced — the cell is forced to direct electrons away from a
damaged respiratory chain membrane to prevent further ROS
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production that will otherwise induce membrane permeability
transition pore opening, cytochrome c release and apoptotic cell
death or necrotic tissue damage (Olsen et al 2013; Cornelius et al
2014b). The survival cost is impaired mitochondrial function,
ROS signalling and repair mechanisms with decreased stress
resistance and disturbed cell growth control. Alternatively, the
decline in mitochondrial respiration and repair mechanisms is
just an inappropriate consequence of stochastic damage to mito-
chondrial function and signalling. The precise molecular mech-
anisms and cellular consequences are still unknown, but certainly
needed in order to know if targeting these pathways by mito-
chondrial enhancer drugs like bezafibrate and resveratrol will
improve or worsen outcome as discussed below.
Limitations and scientific/clinical applicability
of the ROS triangle model
Based on recent studies we have here discussed how IEM, by
production of pathological amounts of ROS, may induce
chronic cell stress with non-resolving or persistent cell repair
responses (first line of adaptive stress responses), or cause
disturbed redox signalling with compromised cell repair re-
sponses (second line of adaptive stress) that make the cells
more susceptible for stress induced cell death. We are aware
that the proposed ROS triangle is a simplified model, not
sufficiently comprehensive to explain the complexity of
chronic disease development, and that many tissue samples
from such diseases will show mixed cell stress responses as
illustrated by the overlapping response curves in Fig. 3a.
These antagonistic cell stress responses seem to be linked to
distinct cellular metabolism through nutrient-sensing signal-
ling growth pathways that control a Warburg-like shift from
mitochondrial respiration towards cytosolic glycolysis. Some
of the components — such as AMPK-linked induction of
antioxidant enzymes, mitophagy and mitochondrial biogene-
sis— have been identified and characterized in some details.
However, others— such as the regulation of the protein qual-
ity control and DNA repair systems, and the mTOR/HIF-1α
mediated antagonistic cell stress responses — remain to be
integrated to understand how to incorporate mitochondrial
stress responses into understanding the altered nutrient-
sensing signalling growth pathway that are increasingly re-
vealed by system biological approaches.
Although we have argued that ROS is the most impor-
tant triggering factor, which also drives the transition from
one stage of the ROS triangle to another, also other mi-
tochondrial signalling molecules like NAD+/NADH, AMP/
ATP, acetyl-CoA, Ca2+, FAD etc. will change accordingly
and add to maintain or progress the cellular stress re-
sponses (Nunnari and Suomalainen 2012; Guha and
Avadhani 2013). Together with ROS, these mitochondrial
signalling molecules allow rapid and specific post-
Fig. 4 Molecular mechanisms of chronic disease progression in which
persistent or increased ROS/damage load and/or decreased levels of
NAD+ drive the transition from AMPK/PGC-1α/FOXO3a-linked repair
responses towards pro-inflammatory responses controlled by the
mTOR/HIF-1α/NF-κB axis. See text for further explanation
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translational regulation of stress proteins within hours of
the stress triggering event and within days/weeks for tran-
scriptional up-regulation of their expression. For longer
lasting stress memory, epigenetic changes are involved.
Metabolic reprogramming, and thereby stress responses,
is determined epigentically (Wallace and Fan 2010; Gut
and Verdin 2013). Therefore, the mechanisms by which
cells cope with stress, through adaptive responses to in-
duce homeostasis and survive, is much more complex than
proposed by the ROS triangle model. To move the model
forward towards clinical applicability it is important to
investigate in more detail the redox and bioenergetics sig-
nalling pathways that drive cellular stress responses and
chronic disease development, and investigate the cellular
consequences of targeting them by antioxidant and mito-
chondrial enhancement treatment.
As discussed above, boosting mitochondrial biogenesis
using pharmacological approaches such as bezafibrate, res-
veratrol and AICAR have been tried in cells from patients
with IEM. Altogether, these ex vivo studies showed in-
creases in FAO and/or OXPHOS capacity and clearly sug-
gest a therapeutic potential of the drugs for ameliorating the
cellular energy deficiency in patients. None of the studies
have investigated the effect of the treatments on oxidative
and inflammatory stress and cell survival, which may well
play an additional role in at least some patients. We have
suggested that down-regulation of mitochondrial respiration,
to decrease the source of ROS, is a cell survival mechanism
to compensate for redox stress and an overloaded repair
system and prevent cell death. Decreasing ROS production
by reducing complex I activity has been shown to be an
essential element in the mitochondrial reprograming induced
by HIF-1α (Tello et al 2011). In this respect the benefit of
mitochondrial enhancement treatment, may be better in the
early phase of disease progression than in later stages, where
irreversible oxidative damage to the respiratory chain has
already occurred and treatment may even be harmful.
Because of the IEM, such artificial and persistent induction
of mitochondrial biogenesis theoretically may increase the
risk of molecular damage spreading into the mitochondrial
network with the risk of promoting further ROS production,
pro-inflammation and/or increased cell death in the long
term. Accordingly, clinical effect of bezafibrate treatment
in patients with long-chain fatty acid oxidation disorders
(Bonnefont et al 2009, 2010; Bastin et al 2014) have been
questioned based on a recent study, where therapeutic effects
were tested during exercise cycle tests (Orngreen et al 2014,
2015). It is likely that toxic levels of ROS — induced by the
combined exercise and bezafibrate treatment — may have
overwhelmed the repair mechanisms and shifted cell stress
adaptation towards pro-inflammatory/death mechanisms.
Alternatively, patient cells showing beneficial effects may
have milder gene defects or be at the early stage of disease
progression, or in a metabolic condition, where activation of
mitochondrial biogenesis and repair mechanisms will allow
the production and selection of a more healthy pool of mi-
tochondria, providing more energy for coping with and
adapting to the gene defects. Similar, variability has been
reported in the biochemical and physiological outcome of
bezafibrate treatment in mouse models of primary
OXPHOS diseases (Komen and Thorburn 2014), reflecting
that translation of ex vivo studies of cells in culture to
in vivo clinical outcomes are not straightforward. Studies
that test the long-term consequences of mitochondrial en-
hancement therapy and monitor metabolic enhancement in
relation to oxidative stress and mitochondrial stress re-
sponses, and in relation to severity (mild versus severe gene
defects) and duration (young versus older patients) of dis-
ease phenotype are therefore highly needed. Also, in those
conditions, where ROS are a major concern, it will be im-
portant to develop or test therapy that can inhibit ROS pro-
duction without interfering with redox regulation of endog-
enous repair mechanisms, and combine such ROS scaveng-
ing therapy with mitochondrial enhancement therapy.
Bezafibrate is a dual activator of PPARα and PPARβ, the
latter one being responsible for improvement in FAO capac-
ity (Bastin 2014). Even though both of these PPARs have
been implicated in alleviating oxidative stress, the exact mo-
lecular mechanisms remain to be elucidated, and their anti-
oxidant properties seem to depend on various metabolic and
pathological conditions (Kim and Yang 2013). In this re-
spect, it may be better to treat with resveratrol. Resveratrol
activates mitochondrial biogenesis at AMPK by boosting
NAD+ and SIRT activities, and will activate not only mito-
chondrial biogenesis but also the antioxidant system and
mitophagy to protect the cells from ROS produced during
mitochondrial biogenesis (Fig. 2). Aerobic exercise is anoth-
er combined mitochondrial antioxidant and enhancement
therapy. Exercise has been shown to increase muscle perfor-
mance in patients with mitochondrial myopathies while part-
ly reverting oxidative stress (Siciliano et al 2012). Finally,
CoQ10 has combined ROS scavenger and mitochondrial
enhancement function (Lee et al 2012), and it has shown
beneficial effects in some IEM, like MERRF (De la Mata
et al 2012). However, in other diseases, including
RR:MADD, CoQ10 has had only minor effects (Cornelius
et al 2013, 2014b). In later disease stages, or during inten-
sive ROS load, the lipid membranes may be too damaged
for CoQ10 or other ROS scavengers to have beneficial ef-
fects, and lipid replacement therapy could be tried (Nicolson
and Ash 2014). In accordance with this theory, MERRF
cells, which show a good response to CoQ10 treatment,
are in the early phase of chronic disease progression with
activation of Bfirst line of adaptive stress responses^.
RR:MADD cells, which show limiting response to CoQ10
treatment, seem to be at a later state of chronic disease
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progression with activation of mostly Bsecond line of adap-
tive stress responses^. These reflections underscore the im-
portance of elucidating the precise mechanisms by which
ROS is produced and propagated in different IEM.
Another challenge for clinical applicability of the ROS tri-
angle model is that because of the metabolic nature of the
stress responses, different stress responses may exist in dif-
ferent tissues (Zhang et al 2013) and even coexist in the
same tissue; ex immune cells (Liu et al 2012).
The establishment of neonatal screening programs for a
number of IEM has enabled early or pre-symptomatic iden-
tification of patients and their causative gene defects. In as
much as oxidative stress and mitochondrial dysfunction may
be an important factor in some of the patient’s disease de-
velopment, new approaches and methods, such as blood
biomarkers and non-invasive imaging techniques, for clini-
cal evaluation of mitochondrial function and stress re-
sponses, are needed for pre-symptomatic prognosis and
treatment decisions. Although still in its infancy, the ROS
triangle model may present a framework to move forward
with new ideas for the design of appropriate experiments to
monitor stress responses and activated nutrient signalling
pathways during disease progression and in response to ther-
apy and disease triggering factors.
Outlook
A recent special issue of Science celebrated a resumed in-
terest in metabolism and discussed a new metabolic para-
digm for disease (Ray 2010). The increasing use of system
biological approaches has driven this new understanding for
disease development with a realization that altered nutrient-
sensing signalling growth pathways and metabolic
reprogramming, towards a more glycolytic metabolism,
drives the initiation or progression of most diseases, like
cancer, diabetes, neurodegenerative diseases, cardiovascular
diseases and IEM. As discussed in the present review, mito-
chondria are absolutely central for this metabolic paradigm
for disease as these organelles do not only provide the cell
with energy and biosynthetic intermediates for cell growth,
but also for support of ROS- and energy-dependent mecha-
nisms like those involved in cell defense and the repair of
cell and tissue damage (Fig. 5). Therefore, to move present
knowledge towards clinical applicability will require scien-
tists to incorporate mitochondrial stress responses and the
principle of the ROS triangle model into understanding the
altered nutrient-sensing signalling growth pathway and met-
abolic reprogramming revealed in many chronic diseases
during the last decade.
Fig. 5 Mitochondria are present in most tissues, and decline in
mitochondrial function and signalling is a common finding in many
chronic diseases and ageing. As such, we suggest that comorbidity is
clinical expression of mitochondrial dysfunction, and that research in
chronic disease development and prevention should be directed towards
targeting mitochondrial signalling and pathways
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